Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925261 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
A Phase 2 study of Knee Osteoarthritis, sponsored by OrthoTrophix.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT01925261: Completed Phase 2 study of Knee Osteoarthritis, sponsored by OrthoTrophix.
NCT01925261 is a Phase 2 study of Knee Osteoarthritis that has completed, run by OrthoTrophix. The registered enrollment target is 120 participants, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01925261, a Phase 2 study of Knee Osteoarthritis, has completed, sponsored by OrthoTrophix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This one-year study is designed to investigate the safety and efficacy of TPX-100, a 23-amino acid chondrogenic peptide, delivered by intra-articular injection, in regeneration of knee cartilage in subjects with bilateral osteoarthritis of the knee.
Primary Outcome
Change in cartilage thickness in the patello-femoral compartment from baseline to 12 months
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TPX-100 50mg
- DRUG TPX-100 100mg
- DRUG TPX-100 200mg
- DRUG TPX-100 20mg
Study Locations (1)
Washington
- C3 Clinical Research Associates - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT01925261 record still lists
NCT01925261 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01925261 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01925261 about?
NCT01925261 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees". This one-year study is designed to investigate the safety and efficacy of TPX-100, a 23-amino acid chondrogenic peptide, delivered by intra-articular injection, in regeneration of knee cartilage in subjects with bilateral osteoarthritis of the knee.
What is the current status of trial NCT01925261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2014-01. Estimated completion is 2016-09.
What conditions does trial NCT01925261 study?
This clinical trial studies the following conditions: Knee Osteoarthritis.
What interventions are being tested in trial NCT01925261?
The interventions under investigation include: Placebo (DRUG), TPX-100 50mg (DRUG), TPX-100 100mg (DRUG), TPX-100 200mg (DRUG), TPX-100 20mg (DRUG).
Who is sponsoring clinical trial NCT01925261?
This trial is sponsored by OrthoTrophix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01925261 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Knee Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01925261's enrollment target sits among peer trials
120 38th of 101 higher than 63 of 101 other Knee Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Knee Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis
RECRUITING · Phase 2
-
Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA
RECRUITING · Phase 2
-
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
RECRUITING · Phase 2
-
Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
RECRUITING · Phase 2
-
Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia